Feasibility and Accuracy of an Ultrasound Algorithm for Acute Dyspnea Diagnosis in the Emergency Department
NCT ID: NCT03691857
Last Updated: 2025-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
225 participants
INTERVENTIONAL
2020-12-14
2025-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inappropriate treatment of acute dyspnea in the ED is frequent (30%) and is associated with a tripling of intra-hospital mortality after adjustment for confounding factors (2.83, IC 1.48 to 5.41, p=0.002). Other elements have also highlighted the importance of a quick and appropriate acute dyspnea diagnosis:
* The 2015 European Guidelines on acute heart failure emphasize the need for appropriate treatment within 90 minutes after the first medical contact.
* Inadequate treatment of chronic bronchitis decompensation is associated with a doubling of intra-hospital mortality.
* An initiation of antibiotic treatment within 4 hours of admission for pneumonia is recommended.
* 30% of pulmonary embolisms are not diagnosed during the initial emergency department visit, whereas their mortality in the absence of treatment is 25%.
Lung, venous and (simplified) cardiac ultrasound is associated with improved diagnostic performance in ED. However, no ultrasound algorithm dedicated to emergency physicians has been formally validated. The Blue Protocol (Lichtenstein et al., Chest 2008) has been validated in intensive care patients with very different phenotypes than those admitted to the ED. Pivetta et al. (Chest 2015) proposed an algorithm focused solely for the diagnosis of heart failure, thus not providing a diagnosis for all the other causes of dyspnea in ED. Finally, Zanbonetti et al. (Chest 2017) proposed an "unguided" ultrasound use, notably integrating inferior vena cava evaluation. However, measuring the inferior vena cava is difficult at the start of ED management when patients are in acute respiratory distress.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contribution and Reproducibility of Lung Ultrasound in the Diagnosis of Acute Heart Failure in the ED
NCT03660592
Focus Thoracic Ultrasound for Dyspnea Diagnosis in Elderly Patient in the Emergency Department
NCT04029051
Evaluation of the Relevance of Diaphragmatic Stroke Ultrasound for the Etiological Diagnosis of Acute Respiratory Distress in an Emergency Department.
NCT06650137
Emergency Department Cardiac Ultrasound
NCT02719509
Prevalence and Kinetics of Diaphragmatic Dysfunction in Elderly Patients With Acute Respiratory Distress
NCT04520815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This primary objective of this prospective multicenter study is to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. Ultrasound exams will be blindly read by a centralized core laboratory after the standardized acquisition of all exams by a physician not involved in the care of patients in the ED. The main discharge diagnosis from initial hospitalization (heart failure, pneumonia and obstructive pulmonary disease exacerbation) will be adjudicated by a college of 3 senior physicians (emergency physician, cardiologist and internist) blinded to the use of ultrasound in the ED.
The secondary objectives of the study are to:
A/ Assess the feasibility of the ultrasound algorithm (EMERALD-US) in emergency departments.
B/ Assess the association between the diagnosis obtained from the ultrasound algorithm (EMERALD-US) and the results of additional (laboratory and radiological exams.
C/ Assess the diagnostic accuracy of the ultrasound algorithm (EMERALD-US) for less frequent dyspnea causes (pulmonary embolism, pleural effusion).
D/ Assess, the diagnostic accuracy of clinical (including BREST and PREDICA score), laboratory and radiological variables.
E/ Assess, the improvement in diagnosis accuracy with the ultrasound algorithm (EMERALD-US) on top of the diagnostic accuracy of clinical, laboratory and radiological exams.
F/ Assess the association between misdiagnosis (without using ultrasound) and survival at D30.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute non-traumatic dyspnea patients
Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
Ultrasound algorithm (EMERALD-US)
Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound algorithm (EMERALD-US)
Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with non-traumatic acute dyspnea managed in the emergency department
* Patients affiliated with a social security system
Exclusion Criteria
* Patients in persistent shock
* Patients with impaired consciousness (Glasgow Score\<9)
* Patients with a history of thoracic surgery or pulmonary fibrosis
* Dementia
* Patients with Acute Coronary Syndrome with ST elevation
* Known current pregnancy
* Patients under guardianship, trusteeship or legal protection
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHOUIHED Tahar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CHOUIHED Tahar
Study chair
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tahar CHOUIHED, MD
Role: PRINCIPAL_INVESTIGATOR
Central Hospital, CHRU de Nancy, France
Nicolas GIRERD, MD PhD
Role: STUDY_CHAIR
CHRU de Nancy, France
Patrick ROSSIGNOL, MD PhD
Role: STUDY_CHAIR
CHRU de Nancy, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH de Chalons en Champagne
Châlons-en-Champagne, , France
Hôpital Simone Veil
Eaubonne, , France
CHRU Nancy
Nancy, , France
AP-HP - Hôpital Cochin
Paris, , France
AP-HP - Hôpital Lariboisière
Paris, , France
CH de Sarreguemines
Sarreguemines, , France
CHRU de Strasbourg, Hôpital de Hautepierre
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alice PENINE, MD
Role: primary
Maxime GAUTIER, MD
Role: backup
Tahar CHOUIHED, MD
Role: primary
Jérôme BOKOBZA, MD
Role: primary
Anthony CHAUVIN, MD
Role: primary
Pierrick Le Borgne, Dr
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Jaeger D, Duchanois C, Duarte K, Lepage X, Merckle L, Bassand A, Buessler A, Chauvin A, Bokobza J, Penine A, Giacomin G, Brossard C, Girerd N, Chouihed T. Performance of an ultrasound diagnostic algorithm for acute dyspneic patients in the emergency department: an EMERALD-US protocol. BMJ Open. 2025 Aug 10;15(8):e101432. doi: 10.1136/bmjopen-2025-101432.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A02136-49
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.